Paul Hastings, Nkarta CEO
Nkarta reveals its first off-the-shelf NK cell data, showing multiple complete responses — shares soar
Nearly two years after pricing its IPO, Nkarta is finally reporting its first clinical data Monday.
The South San Francisco biotech revealed the first human …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.